BEDMINSTER, N.J.--(BUSINESS WIRE)-- Results from the CLUE study, a head-to-head comparison between Ready-to-Use Cardene ® I.V. (nicardipine) and labetalol in the emergency room, showed that ...

EKR Therapeutics has launched its single-use Cardene IV Ready-to-Use Bag (nicardipine HCl premixed injection) for the short-term treatment of hypertension when oral therapy is not feasible or ...

EKR Therapeutics has received FDA approval for double concentration Cardene IV (nicardipine HCl premixed injection) for the short-term treatment of hypertension when oral therapy is not feasible or ...

CEDAR KNOLLS, NJ and REDWOOD CITY, CA, Feb 04, 2008 -- EKR Therapeutics, Inc. and PDL BioPharma today announced that they have entered into an agreement under which EKR would acquire the rights to PDL ...

American Regent is introducing nicardipine hydrochloride injection. The product, which is a generic of EKR Therapeutics’ Cardene, is a calcium channel blocker indicated for the short-term treatment of ...

Nicardipine Hydrochloride capsules are the generic version of Cardene1 Capsules. IQVIATM sales data for the 12-month period ending October 2022 shows that the Cardene® Capsules achieved annual sales ...

("Cornerstone" or "the Company") filed a Complaint earlier today in the United States District Court for the District of Delaware alleging that Exela Pharma Sciences, LLC, Exela PharmSci, Inc., and ...

CARY, NC--(Marketwired - Jun 13, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone" or the "Company") today announced that on June 11, 2013 the Company received a Paragraph IV Notice ...